Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 2/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 5/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30162956 | 0.81 | CDK4 (0.39) | MEN1KMT2AHPGDALDH1A1HSD17B10 | |
| SCHEMBL22868260 | 0.81 | CDK4 (0.39) | MEN1KMT2AHPGDALDH1A1HSD17B10 | |
| SCHEMBL5416880 | 0.81 | CDK4 (0.40) | HSD17B10DRD2DRD3DAOGRIN2D | |
| SCHEMBL4850347 | 0.73 | HTR1A (0.55) | HPGDALDH1A1HSD17B10USP2DRD2 | |
| SCHEMBL7908126 | 0.72 | DRD2 (0.43) | DRD2DRD3HTR1AHTR2AHTR2C | |
| SCHEMBL7350618 | 0.71 | HTR1A (0.66) | DRD2DRD3HTR1A | |
| SCHEMBL17106117 | 0.70 | HSD17B10 (0.44) | HPGDALDH1A1HSD17B10USP2KDM4E | |
| SCHEMBL4573122 | 0.69 | HTR1A (0.54) | DRD2DRD3HTR1A | |
| SCHEMBL4859067 | 0.69 | NPC1 (0.42) | DRD2DRD3KDM4EDAOHTR1A | |
| SCHEMBL261519 | 0.67 | CALCRL (0.34) | MEN1KMT2AHSD17B10DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745299-B2 | Substituted tricyclic benzimidazoles as kinase inhibitors | SELVITA SA (PL) | 2017-08-29 | — | — | US | disclosed |
| US-9745299-B2 | Substituted tricyclic benzimidazoles as kinase inhibitors | SELVITA SA (PL) | 2017-08-29 | — | — | US | disclosed |
| US-9745299-B2 | Substituted tricyclic benzimidazoles as kinase inhibitors | SELVITA SA (PL) | 2017-08-29 | — | — | US | disclosed |
| EP-2917217-B1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS | SELVITA S A (PL) | 2017-03-08 | — | — | EP | disclosed |
| EP-2917217-B1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS | SELVITA S A (PL) | 2017-03-08 | — | — | EP | disclosed |
| US-20150274726-A1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS | SELVITA SA (PL) | 2015-10-01 | — | — | US | disclosed |
| WO-2014072435-A1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS | SELVITA SA (PL) | 2014-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274726-A1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS | CDK8, CDK18, CDK9 | MEN1 1786/4885KMT2A 238/4885MAPK1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.